Given that PD-L1 is an immunoinhibitory protein, its systemic introduction into the context of RA could lead to two potential outcomes: it might alleviate symptoms on a systemic level, or it could introduce adverse effects, including immune dysfunction, among others. This evidence concerns the gene CD274 and immune system disorder.